Safety and Efficacy of KPI-121 in Subjects With DED
- Conditions
- Kerato Conjunctivitis Sicca
- Interventions
- Drug: KPI-121 Ophthalmic SuspensionDrug: Vehicle
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2021-04-02
- Lead Sponsor
- Kala Pharmaceuticals, Inc.
- Target Recruit Count
- 901
- Registration Number
- NCT03616899
- Locations
- πΊπΈ
Investigator #278, Dothan, Alabama, United States
πΊπΈInvestigator #213, Westminster, California, United States
πΊπΈInvestigator #268, Roswell, Georgia, United States
KPI-121 1% Versus Prednisolone for the Treatment of Inflammation Following Cataract Surgery in Children
- Conditions
- Ocular Inflammation
- Interventions
- Drug: KPI-121 1%
- First Posted Date
- 2018-07-24
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Kala Pharmaceuticals, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT03596723
- Locations
- πΊπΈ
Children's Eye Care, PC, Detroit, Michigan, United States
πΊπΈByers Eye Institute at Stanford University, Palo Alto, California, United States
πΊπΈHouston Eye Associates, The Woodlands, Texas, United States
Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease
- Conditions
- Keratoconjunctivitis SiccaDry Eye Syndromes
- Interventions
- Drug: Vehicle of KPI-121 0.25% Ophthalmic SuspensionDrug: KPI-121 0.25% Ophthalmic Suspension
- First Posted Date
- 2016-06-30
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Kala Pharmaceuticals, Inc.
- Target Recruit Count
- 909
- Registration Number
- NCT02819284
- Locations
- πΊπΈ
Arizona Eye Center, Chandler, Arizona, United States
πΊπΈHernando Eye Institute, Brooksville, Florida, United States
πΊπΈShettle Eye Research, Inc, Largo, Florida, United States
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
- Conditions
- Keratoconjunctivitis SiccaDry Eye Syndromes
- Interventions
- Drug: KPI-121 0.25% Ophthalmic SuspensionDrug: Vehicle of KPI-121 0.25% Ophthalmic Suspension
- First Posted Date
- 2016-06-24
- Last Posted Date
- 2021-02-03
- Lead Sponsor
- Kala Pharmaceuticals, Inc.
- Target Recruit Count
- 918
- Registration Number
- NCT02813265
- Locations
- πΊπΈ
Cornea and Cataract Consultants of Arizona, Phoenix, Arizona, United States
πΊπΈSchwartz Laser Eye Center, Scottsdale, Arizona, United States
πΊπΈEyecare Arkansas, P.A., Little Rock, Arkansas, United States
Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain
- Conditions
- Post Surgical Ocular Inflammation and Pain
- Interventions
- Drug: KPI-121 1% Ophthalmic Suspension dosed BIDDrug: Vehicle of KPI-121 Ophthalmic Suspension dosed BID
- First Posted Date
- 2016-06-08
- Last Posted Date
- 2020-12-16
- Lead Sponsor
- Kala Pharmaceuticals, Inc.
- Target Recruit Count
- 520
- Registration Number
- NCT02793817
- Locations
- πΊπΈ
Apex Eye, Cincinnati, Ohio, United States
πΊπΈSall Research Medical Center, Artesia, California, United States
πΊπΈArizona Eye Center, Chandler, Arizona, United States
Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema
- Conditions
- Retinal Vein OcclusionDiabetic Macular Edema
- Interventions
- Drug: KPI-121 1.0% Ophthalmic SuspensionDrug: KPI-121 0.25% Ophthalmic Suspension
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2020-12-10
- Lead Sponsor
- Kala Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT02245516
- Locations
- πΊπΈ
Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
πΊπΈRetina-Vitreous Associates Medical Group, Beverly Hills, California, United States
Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease
- First Posted Date
- 2014-08-18
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- Kala Pharmaceuticals, Inc.
- Target Recruit Count
- 206
- Registration Number
- NCT02218489
- Locations
- πΊπΈ
Abrams Eye Center, Cleveland, Ohio, United States
πΊπΈSall Research Medical Center, Artesia, California, United States
πΊπΈWolstan & Goldberg Eye Associates, Torrance, California, United States
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
- Conditions
- Dry Eye SyndromesKeratoconjunctivitis Sicca
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-07-11
- Last Posted Date
- 2021-01-06
- Lead Sponsor
- Kala Pharmaceuticals, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT02188160
- Locations
- πΊπΈ
Eye Center of Southern CT, P.C., Hamden, Connecticut, United States
πΊπΈTotal Eye Care, PA, Memphis, Tennessee, United States
πΊπΈMartel Eye Medical Group, Rancho Cordova, California, United States
Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation
- Conditions
- Ocular Infections, Irritations and Inflammations
- Interventions
- First Posted Date
- 2014-06-16
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- Kala Pharmaceuticals, Inc.
- Target Recruit Count
- 380
- Registration Number
- NCT02163824
- Locations
- πΊπΈ
Westside Research, LLC, Spartanburg, South Carolina, United States
πΊπΈPrice Vision Group, Indianapolis, Indiana, United States
πΊπΈSall Research Medical Center, Artesia, California, United States